Tag: Interstitial Lung Disease
Objective: Interstitial lung disease (ILD) is the most severe complication of idiopathic inflammatory myositis (IIM), resulting in significant increase in morbidity and mortality and for which the best treatment remains controversial. We conducted a meta-analysis to evaluate the efficacy of therapies used for the management of IIM-related ILD
Interstitial lung disease (ILD) is the leading cause of death in patients with systemic sclerosis (SSc). Randomized controlled trials have favored the use of cyclophosphamide (CYC) for treating SSc-ILD3,4,5. Compared with placebo, 1 year of CYC improved lung function in patients with SSc-ILD in Scleroderma Lung Study (SLS) I3